Silence Before the Answer on GLP-1 Drug Resistance
The room went quiet. Not the kind of silence that follows a finished sentence. The kind that happens when data does something it should not. A screen showed numbers that contradicted every expectation the researchers had carried into the experiment. They had come looking for low hormone levels. They found high ones instead. Nobody spoke for a moment because nobody knew what to say.
That silence lasted years.
The Human Story: Who Carries the Quirk
Mahesh Umapathysivam sees patients every week in his endocrinology clinic at Adelaide University in Australia. [1] He watches them take the same drug and get completely different results. Some lower their blood sugar fast. Others barely budge. He has no way to tell who will respond before prescribing. This frustrates him because diabetes treatment should not be a guessing game. Anna Gloyn at Stanford Medicine has spent a decade chasing this [2]problem. She is a professor of pediatrics and genetics. Her office walls could hold maps of human chromosomes. She knows that biology rarely gives simple answers. But she also knows that when a patient fails therapy, the clock starts ticking toward complications like kidney damage or vision loss. Markus Stoffel at ETH Zurich in Switzerland studies metabolism at the mole [3]cular level. His laboratory at the Institute of Molecular Health Sciences has tools to edit genes in mice. He can create animals with specific genetic modifications and observe the effects on metabolism. This matters because human experiments can only show correlation. Mouse experiments can show causation. Elisa Araldi at the University of Parma in Italy trained with Stoffel before becoming an asso [5]ciate professor. She understands that the path from a genetic variant to a clinical outcome passes through dozens of biological steps. Each step is a place where things can go wrong, Araldi explained.These four scientists, spread across continents, connected by a single question: Why do some people resist GLP-1 drugs?
The Scientific Story: What the Variant Does
The human genome contains roughly 3 billion base pairs. Most are identical between any two people. A tiny fraction differs. Among those differences sit two variants that caught the researchers’ attention. They are called p.S539W and p.D563G. Both affect a gene that codes for an enzyme named PAM — peptidyl-glycine alpha-amidating monooxygenase.
PAM is the only enzyme in the human body capable of amidation. This chemical process attaches a small molecular cap onto certain hormones. Without that cap, the hormones degrade faster or lose potency. Think of it like putting a lid on a water bottle. Without the lid, the water spills. Without amidation, the hormone spills out of usefulness.
GLP-1 is one of those hormones. It gets released from the gut after eating. It tells the pancreas to release insulin. It slows down stomach emptying so food enters the bloodstream gradually. It signals the brain to feel full. These three actions together keep blood sugar stable.
The PAM enzyme should activate GLP-1 through amidation. The genetic variants reduce PAM activity. So the researchers expected less active GLP-1 in carriers. They designed their experiment accordingly.
The Human Story: The Sugar Drink Test
The team recruited adults w [1]ith and without the p.S539W variant. They excluded people with diabetes to avoid other factors muddying the results. [2] Each participant drank a sugary solution. Then a nurse drew blood every five minutes for four hours.
That is 48 blood draws per person.
Umapathysivam coordinated this part of the study. He watched the tubes fill and labeled each one carefully. The samples traveled to analyzers that measured amidated GLP-1 levels. The researchers expected to see lower numbers in the variant carriers. That would confirm their hypothesis.
The first batch of results arrived on an afternoon.
The Scientific Story: The Opposite Result
The [3] carriers had higher GLP-1 levels than non-carriers. Not slightly higher. Consistently higher across the entire four-hour window. Their bodies were producing more of the hormone, not less.
Gloyn remembers staring at the numbers. “This was the opposite of what we imagined we would find,” she said later. [2] The logic seemed inverted. If PAM activates GLP-1, and the variant reduces PAM activity, then GLP-1 should be lower. But it was higher.
The body sometimes compensates for inefficiency by producing more of something. If a factory makes defective products, the manager might increase production to meet demand. The same principle might apply here. The hormone was being made, but it was not working properly. So the body made more of it.
But more did not equal better. Despite the elevated GLP-1, carriers showed no increase in biological activity. Their blood sugar did not drop faster. Their insulin did not rise more. More GLP-1 was needed to achieve the same effect. That is the definition of resistance.
The Human Story: The Years of Doubt
Gloyn did not trust her own data. Neither did her collaborators. They spent several years trying to disprove what they had found. They ran the experiment again with different participants. They used different assays to measure GLP-1. They analyzed the samples in different laboratories.
“We couldn’t understand this, which is why we looked as many different ways as we could to see if this was a really robust observation,” Gloyn said.
Umapathysivam kept seeing patients while the science progressed. He prescribed GLP-1 drugs to some who carried the variant. He watched their blood sugar charts plateau. HeThe team published their findings in Genome Medicine in June 2026. The paper lists authors from Stanford, ETH Zurich, Adelaide University, the University of Parma, and collaborators in Copenhagen. The work spanned 10 years from first idea to final publication. The work spanned 10 years from first idea to final publication.
The Scientific Story: Mouse Models Confirm
Stoffel’s team in Zurich had developed mice that lacked the PAM gene entirely. [3] These animals offered a clean test. If the variant caused resistance in humans, the knockout mice should show similar patterns.
They did.
The mice had elevated GLP-1 levels. [4] The hormone was less effective at controlling blood sugar. One of GLP-1’s major jobs is slowing gastric emptying — the rate at which food leaves the stomach and enters the small intestine. This delay helps regulate how quickly glucose appears in the bloodstream. It also contributes to the feeling of fullness that aids weight loss.
Mice without PAM showed faster gastric emptying. When the researchers gave them a GLP-1 receptor agonist, the drug failed to slow the process down. The stomach kept emptying at its natural speed, ignoring the medication.
The researchers also tested responses in the pancreas and digestive tract separately. Both showed weaker reactions to GLP-1. But the number of GLP-1 receptors on cell surfaces remained unchanged. The problem was not that the receptors were missing. The problem was somewhere downstream, inside the cell, in the signaling chain that follows receptor activation.
Working with scientists in Copenhagen, the team confirmed that PAM defects do not interfere with GLP-1 binding to its receptor. The hormone can still dock at the cell surface. The lock works. But the door does not open properly.
The Human Story: Clinical Trial Data
The laboratory evidence was strong. But it meant nothing if it did not translate to real patients. The team needed access to clinical trial data — actual people taking actual diabetes drugs and having their blood sugar measured over time.
They obtained data from three clinical trials involving 1,119 participants with Type 2 diabetes. All participants had received GLP-1 receptor agonists. Their HbA1c levels — a measure of average blood sugar over three months — were recorded before and after six months of treatment.
The numbers told a stark story.
Among participants without the ge [1]netic variants, approximately 25% reached the recommended HbA1c target after six months. Among carriers of the p.S539W variant, only 11.5% achieved that goal. For carriers of the p.D563G variant, the figure was 18.5%.
These are not small differences. A patient carrying p.S539W is roughly half as likely to reach blood sugar targets as someone without it. The variant effectively cuts the drug’s success rate in that population.
Gloyn noted that physicians typically consider changing a patient’s treatment plan after six months if targets are not met. “Identifying likely responders in advance could help patients reach the most effective therapy sooner,” she said. This moves diabetes care closer to precision medicine — matching the drug to the patient’s biology rather than treating everyone the same way.
The Scientific Story: What the Variants Do Not Affect
The researchers checked whether the same genetic variants influenced responses to other diabetes medications. They tested sulfonylureas, metformin, and DPP-4 inhibitors. None showed any effect from the PAM variants.
This is important because it narrows the mechanism. The variants do not cause general drug resistance. They specifically impair response to GLP-1-based therapies. The problem is hormone-specific, not drug-class-general.
The team also did not reach firm conclusions about weight loss. Drugs like Ozempic and Wegovy are prescribed at higher doses for obesity than for diabetes. The study focused on blood sugar control. Whether the same genetic factors influence weight loss outcomes remains unknown. More research is needed.
The Human Story: The 10% Who Carry It
Roughly 10% of the general population carries one of these PAM variants. That is 800 million people worldwide. Most do not know they have it. There is no routine genetic test for it. No doctor checks for it before prescribing Ozempic.
Umapathysivam treats patients who might carry the variant without knowing. He cannot tell by looking at them. He cannot tell by asking about their family history. The variant is silent until a drug fails to work.
“When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically,” he said. “This is the first step in being able to use someone’s genetic make-up to help us improve that decision-making process.”
The step from discovery to clinical practice is long. A genetic test must be developed, validated, and approved. Insurance companies must decide whether to cover it. Doctors must learn to interpret it. Patients must consent to it. None of this happens quickly.
The Scientific Story: The Million-Dollar Question
Gloyn calls it “the million-dollar question.” The team has identified the genetic variants. They have confirmed the resistance in humans and mice. They have ruled out receptor binding problems. They have shown the effect in clinical trials.
But they do not know exactly why.
“That is the million-dollar question,” Gloyn said. “We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we’ve done, we’ve not been able to nail precisely why they are resistant.”
The enzyme PAM activates multiple hormones, not just GLP-1. It also affects gastrin, cholecystokinin, and other peptides involved in digestion and metabolism. A defect in PAM could create a cascade of hormonal imbalances. The GLP-1 resistance might be a symptom of a broader metabolic disruption.
“We thought, if you have a problem with this enzyme, there’s going to be multiple aspects of your biology that are not working properly,” Gloyn said.
The downstream signaling pathway — the chain of events inside the cell after GLP-1 binds to its receptor — remains poorly mapped. The Copenhagen experiments showed that binding is normal. The problem lies deeper. Finding it requires tracing every molecular handshake from the cell surface to the nucleus.
The Human Story: What This Means for Patients
A patient named Maria (not her real name) has Type 2 diabetes. She takes Ozempic. Her blood sugar improves but does not reach target. Her doctor increases the dose. Still not enough. They add metformin. Better, but not great. Maria wonders why the drug that works for her neighbor does not work for her.
If Maria carries a PAM variant, she now has a partial answer. The drug is not failing because of something she did wrong. It is failing because of something in her DNA. This knowledge can shift blame from behavior to biology.
For the 25% of non-carriers who also do not reach target, the explanation remains unclear. Genetics is only one piece of a larger puzzle. Diet, exercise, gut microbiome, other medications, and disease duration all play roles. The PAM variants explain some of the variation, not all of it.
The Scientific Story: Broader Implications
The concept of hormone resistance is not new. Insulin resistance is the hallmark of Type 2 diabetes itself. The body produces insulin but cannot use it effectively. Now the same concept applies to GLP-1. Some people produce plenty of the hormone but cannot respond to it.
This raises a question: Could GLP-1 resistance precede diabetes? If a person has trouble responding to GLP-1, their blood sugar regulation might be compromised even before insulin resistance develops. The variant might be a risk factor, not just a treatment modifier.
The researchers did not test this. Their study focused on people already diagnosed with diabetes. But the possibility exists. If GLP-1 resistance is an early defect, screening for PAM variants could identify people at higher risk years before they develop high blood sugar.
The Human Story: The International Collaboration
The study brought together scientists from Stanford Medicine, ETH Zurich, Adelaide University, the University of Parma, and research groups in Copenhagen. Each site contributed a different piece of the puzzle.
Stanford provided the human genetics expertise. Zurich contributed the mouse models. Adelaide brought clinical trial data and patient perspectives. Parma helped with molecular analysis. Copenhagen solved the receptor binding question.
This kind of collaboration is expensive and slow. It requires trust. It requires sharing data before publication. It requires patience when results contradict expectations. The team spent a decade together, meeting across time zones, arguing about methodology, and slowly converging on a shared conclusion.
The Scientific Story: The PAM Enzyme in Detail
PAM is encoded by a gene on chromosome 5 in humans. The enzyme operates in the secretory pathway of cells — the assembly line that packages hormones for release. It performs amidation, which is the addition of a glycine-derived amide group to the end of a peptide chain.
This modification can increase a hormone’s half-life by protecting it from degradation. It can also enhance potency by improving how the hormone fits into its receptor. Without amidation, some hormones become floppy and ineffective.
The two variants identified in the study — p.S539W and p.D563G — are single-letter changes in the PAM protein. A serine becomes a tryptophan at position 539. An aspartate becomes a glycine at position 563. These substitutions alter the enzyme’s shape and reduce its activity.
Previous research had already linked PAM variants to diabetes risk. Gloyn had shown that these variants impair insulin secretion from the pancreas. The current study extends that finding to GLP-1 resistance, suggesting PAM affects multiple aspects of glucose metabolism.
The Human Story: The Patients Who Drove the Research
Umapathysivam’s clinical experience shaped the study’s direction. He saw the variation in drug response every day. He wondered whether genetics could explain it. He brought this question to Gloyn, his former mentor, and asked whether they could find an answer.
The patients who participated in the sugar drink test gave their time and blood without knowing whether the study would find anything. They sat for four hours with needles in their arms. They trusted that the science would eventually help someone, even if not themselves.
The clinical trial participants whose data was analyzed had signed consent forms years earlier. They had taken their medications as prescribed. They had returned for follow-up visits. Their anonymized data became the evidence that confirmed the laboratory findings.
The Scientific Story: The Limits of Current Knowledge
The study has several limitations. It focused on HbA1c as the primary outcome. This is a standard measure of blood sugar control, but it does not capture day-to-day fluctuations or post-meal spikes. Continuous glucose monitoring might reveal more nuanced differences between carriers and non-carriers.
The clinical trials analyzed included mostly participants of European ancestry. The frequency of PAM variants may differ in other populations. Whether the same effects occur in people of African, Asian, or Latin American descent remains unknown.
The weight loss question remains open. GLP-1 drugs are now widely used for obesity. If PAM variants also blunt weight loss effects, millions of people might be taking medications that work poorly for their specific biology. The researchers explicitly stated that they “did not reach firm conclusions about weight loss effects.”
The Human Story: The Next Steps
Gloyn’s laboratory continues to investigate the mechanism. They are mapping the downstream signaling pathway to find exactly where the resistance occurs. This could reveal new drug targets — molecules that could be modulated to overcome the resistance.
Umapathysivam is working on a clinical tool that could predict drug response based on genetics. This would require a simple blood test or cheek swab. The result would tell the doctor whether a patient is likely to benefit from a GLP-1 drug or should try a different class of medication first.
Stoffel’s team is developing mouse models with specific PAM mutations to study the resistance mechanism in more detail. They want to know whether the effect is limited to GLP-1 or affects other amidated hormones as well.
The team also plans to study whether PAM variants influence weight loss outcomes in obesity trials. If the effect is similar, the implications extend beyond diabetes to the millions of people taking GLP-1 drugs for weight management.
The Scientific Story: The Broader Context of Precision Medicine
Diabetes treatment has historically followed a one-size-fits-all approach. Patients receive metformin first, then add other drugs based on guidelines that apply to the average person. The average person does not exist. Each patient has a unique genetic profile, microbiome, lifestyle, and disease trajectory.
Precision medicine aims to match treatments to individual biology. This already happens in cancer, where tumors are sequenced to identify mutations that predict drug response. Diabetes has lagged behind because the genetics are more complex. Dozens of genes influence drug response, each with a small effect.
The PAM variants are unusual because their effect size is relatively large. A single variant can cut drug response by half. This makes them clinically actionable. A genetic test for PAM could identify the 10% of patients who are unlikely to respond well to GLP-1 drugs.
The Human Story: The Doctor’s Dilemma
Umapathysivam faces a dilemma every time he prescribes a GLP-1 drug. He knows that 1 in 10 of his patients may carry a variant that makes the drug less effective. He has no way to identify them. He prescribes the drug, waits six months, checks the HbA1c, and then decides whether to continue or switch.
Six months is a long time to waste on an ineffective treatment. Meanwhile, blood sugar remains high. Damage accumulates. The patient loses confidence in the medical system. The doctor feels frustrated.
A genetic test could change this. The patient would take a test before starting treatment. The result would guide the initial prescription. If the variant is present, the doctor might start with a different drug class — perhaps a sulfonylurea or DPP-4 inhibitor, which showed no effect from the variant.
The Scientific Story: The Economics of Genetic Testing
Genetic testing costs money. A single test might cost $100 to $500, depending on the method. Insurance companies must decide whether this cost is justified by improved outcomes. If testing prevents six months of ineffective treatment, the savings in drug costs alone might offset the test price.
GLP-1 drugs are expensive. Ozempic costs roughly $900 per month without insurance. Six months of ineffective treatment costs $5,400. A one-time genetic test for a fraction of that cost becomes economically rational.
But the healthcare system does not always follow economic logic. Adoption of new tests requires guidelines from professional societies, approval from regulatory agencies, and education of clinicians. All of this takes years.
The Human Story: The Patient’s Perspective
Imagine being told that your diabetes medication is not working because of a quirk in your DNA. You did not cause it. You cannot change it. But you can work around it.
For some patients, this knowledge brings relief. It removes the guilt of “failing” a medication. It replaces self-blame with biological understanding. It opens the door to a different treatment that might work better.
For other patients, the knowledge might feel like a burden. Another thing to worry about. Another label. Another way that their body does not cooperate. The psychological impact of genetic information varies widely.
The Scientific Story: The History of GLP-1 Research
The discovery of GLP-1 dates back to the 1980s, when researchers identified the hormone as a product of the proglucagon gene. They found that it stimulates insulin secretion in response to food intake. This made it an attractive target for diabetes treatment.
The first GLP-1 receptor agonist, exenatide, was approved in 2005. It was derived from the saliva of the Gila monster, a lizard that eats infrequently and needs a burst of insulin after meals. Exenatide was a breakthrough, but it required twice-daily injections and caused nausea.
Newer drugs like semaglutide (Ozempic, Wegovy) last longer and cause fewer side effects. They are taken once weekly. Their popularity exploded after clinical trials showed dramatic weight loss effects. Today, GLP-1 drugs are among the best-selling medicationsGloyn trained as a geneticist at the University of Oxford before moving to Stanfordry. It suggests that even the best drugs do not work for everyone, and that biology — not marketing — should determine who gets them.
The Human Story: The Scientists Themselves
Gloyn trained as a ge [8]neticist at the University of Oxford before moving to Stanford. She has spent her career studying the genetics of diabetes. She knows that every discovery raises more questions than it answers.
Stoffel is a physician-scientist who trained at the University of Zurich and MIT. He has published extensively on metabolism and gene regulation. His work often bridges basic science and clinical application.
Umapathysivam completed his medical training in Australia before pursuing a doctorate with Gloyn. He now splits his time between seeing patients and running experiments. He embodies the bridge between clinic and laboratory.
Araldi trained in Italy and Switzerland before returning to Parma. She brings expertise in molecular biology and hormone signaling.
These four scientists, along with their teams, represent a decade of collaborative effort. They published their findings in Genome Medicine in June 2026. The paper is open access, meaning anyone can read it without a subscription.
The Scientific Story: The Data That Changed Everything
The sugar drink experiment produced the first surprise. The mouse studies confirmed the surprise was real. The clinical trial data showed the surprise had practical consequences.
Each step built on the previous one. The human experiment raised the hypothesis. The mouse experiment tested the hypothesis under controlled conditions. The clinical trial data validated the hypothesis in real-world settings.
This is how science works at its best. A finding in one context is tested in another. If it holds up, confidence grows. If it does not, the hypothesis is revised or abandoned.
The PAM finding held up across all three contexts. That is why the researchers are confident enough to publish it, even though they cannot yet explain the mechanism.
The Human Story: The Unanswered Questions
Gloyn’s team has ticked off an enormous list of possible explanations for GLP-1 resistance. They have ruled out receptor binding problems. They have ruled out receptor number changes. They have ruled out general drug resistance.
What remains is a black box inside the cell. Somewhere between the receptor and the cellular response, the signal gets lost. Finding that missing link is the next challenge.
Umapathysivam wonders whether the resistance can be overcome with higher drug doses. The clinical trials used standard doses. Maybe carriers need more medication to achieve the same effect. Or maybe no dose can compensate for the biological defect.
Stoffel wonders whether the PAM variants affect other hormones in ways that contribute to metabolic disease. If PAM is the only enzyme that performs amidation, its dysfunction could have widespread effects.
The Scientific Story: The Future of Diabetes Treatment
Imagine a future where every diabetes patient gets a genetic test before starting medication. The test reveals whether they carry PAM variants. The doctor uses this information to choose the initial drug.
For carriers, the doctor might prescribe a sulfonylurea or DPP-4 inhibitor instead of a GLP-1 drug. These medications work through different pathways and are unaffected by the PAM variants.
For non-carriers, the doctor might start with a GLP-1 drug, knowing that the patient is likely to respond well.
This future is not science fiction. The genetic test already exists in research settings. It just needs to be validated, standardized, and made available in clinics.
The Human Story: The 10% Who Could Benefit
800 million people worldwide carry PAM variants. Not all of them have diabetes. Not all of them take GLP-1 drugs. But for those who do, the information could change their treatment trajectory.A patient who knows they carry the variant can have an informed conversation with their doctor. They can ask whether a different drug might work better. They can set realistic expectations about their response to treatment.
A patient who does not know they carry the variant continues to take a drug that may not work well. They may blame themselves for the poor results. They may stop taking the medication altogether, losing any benefit it might provide.
The difference between knowing and not knowing is a simple genetic test.
The Scientific Story: The Role of Serendipity
The discovery of GLP-1 resistance was not planned. The researchers set out to test a straightforward hypothesis: PAM variants reduce GLP-1 levels. They found the opposite.
Science often works this way. The most important discoveries come from unexpected results. If the data had confirmed their hypothesis, the finding would have been less interesting. Low GLP-1 levels are easy to explain. High levels with low activity are mysterious.
The mystery drove the research forward. It forced the team to look harder, test more rigorously, and collaborate more broadly. The result is a finding that would not have emerged from a confirmatory study.
The Human Story: The Weight of Ten Years
Ten years is a long time to spend on a single question. Grants were written and rewritten. Students joined and graduated. Collaborators came and went. The question remained unanswered through most of that decade.
Gloyn kept the project alive because she believed the answer mattered. Umapathysivam kept working because he saw the clinical need. Stoffel kept funding the mouse work because the human data was compelling.
The publication in Genome Medicine marks the end of one phase and the beginning of another. The question has been identified and confirmed. Now the mechanism must be found.
The Scientific Story: The Parallels to Other Fields
Hormone resistance is not unique to GLP-1. Insulin resistance is the foundation of Type 2 diabetes. Leptin resistance contributes to obesity. Thyroid hormone resistance is a rare genetic condition. Each involves a hormone that is present but not fully effective.
The concept of genetic variation affecting drug response is called pharmacogenomics. It applies to many drugs beyond diabetes medications. Warfarin dosing depends on genetic variants in CYP2C9 and VKORC1. Codeine effectiveness depends on CYP2D6 activity. Abacavir can cause severe reactions in people with the HLA-B5701 variant.
GLP-1 drugs now join this growing list of medications where genetics matters. The PAM variants are the first genetic markers for GLP-1 response, but they will not be the last.
The Human Story: The Global Collaboration
The study involved researchers from four countries on three continents. They spoke different languages, worked in different time zones, and navigated different funding systems. They shared data, reagents, and ideas across borders.
This kind of collaboration is increasingly common in modern science. No single laboratory has all the expertise needed to solve complex problems. The PAM story required human genetics, mouse genetics, clinical trials, and molecular biology. No one team could do all of it.
The collaboration also reflects the global nature of diabetes. The disease affects 500 million people worldwide. Solutions must come from a global scientific community.
The Scientific Story: The Statistical Power
The clinical trial analysis included 1,119 participants. This is a relatively large sample for a genetic study of drug response. The effect sizes were large enough to reach statistical significance despite the relatively small number of variant carriers.
Among non-carriers, 25% reached HbA1c targets. Among p.S539W carriers, 11.5% reached targets. This difference has a p-value below 0.05, meaning it is unlikely to be due to chance.
The researchers also checked for population stratification — the possibility that the variant is more common in certain ethnic groups that might respond differently for other reasons. They controlled for this in their analysis.
The Human Story: The Patients Who Will Benefit
The first patients to benefit from this discovery will be those who participate in future clinical trials of genetic testing They will receive a test, learn their carrier status, and have their treatment guided accordingly.
If those trials show benefit, the testing may become standard of care. Guidelines from the American Diabetes Association and European Association for the Study of Diabetes may recommend genetic screening before prescribing GLP-1 drugs.
This process takes years. But it moves forward one study at a time. The PAM discovery is the first study in that chain.
The Scientific Story: The Open Questions
The researchers have identified the variants. They have confirmed the resistance. They have shown the clinical impact. But several questions remain unanswered.
Why do carriers produce more GLP-1 if the hormone is less effective? Is it a compensation mechanism or a direct effect of PAM dysfunction?
Where exactly does the resistance occur in the signaling pathway? Which proteins downstream of the receptor are affected?
Can the resistance be overcome with higher doses of GLP-1 drugs? Or is the ceiling effect fixed?
Do the variants affect weight loss outcomes? The study did not answer this question.
Are there other genetic variants that also cause GLP-1 resistance? The PAM variants explain only part of the variation in drug response.
The Human Story: The Emotional Arc
The researchers experienced a full emotional arc during this project. Excitement at the initial finding. Doubt when the results seemed too strange. Persistence through years of replication. Relief when the mouse studies confirmed the human data. Validation when the clinical trial data showed the effect.
Gloyn described the process as humbling. “We thought we understood how GLP-1 worked,” she said. “This showed us we had more to learn.”
Umapathysivam described it as motivating. “Now we have a target,” he said. “We know what to look for.”
The Scientific Story: The Mechanism of Amidation
Amidation is a chemical modification that occurs after a hormone is synthesized. The cell produces a precursor protein, then cuts it into smaller peptides, then modifies those peptides to make them active.
PAM performs the final modification step. It adds an amide group to the C-terminus of the peptide. This amide group can increase the peptide’s half-life by protecting it from degradation by enzymes called exopeptidases.
Without amidation, GLP-1 might be broken down too quickly to have much effect. But the researchers found that carriers actually have more GLP-1, not less. This suggests the body compensates by producing more precursor, even though the final product is less stable or less potent.
The Human Story: The Next Generation of Researchers
The study trained several early-career scientists. Umapathysivam was a former trainee with Gloyn. Araldi was a former trainee with Stoffel. These young researchers will carry the work forward.
They will train their own students. They will ask new questions. They will develop new tools. The discovery of GLP-1 resistance is not the end of a story. It is the beginning of a new research direction.
The Scientific Story: The Clinical Implications
For clinicians, the finding adds a new consideration to prescribing decisions. A patient with a family history of poor response to GLP-1 drugs might benefit from genetic testing. A patient who fails to respond to a GLP-1 drug might be tested to see whether a genetic variant explains the failure.
For patients, the finding offers an explanation. If a GLP-1 drug does not work well, it may not be the patient’s fault. It may be their biology.
For researchers, the finding opens new avenues. The downstream signaling pathway can now be mapped. New drug targets may emerge. Better treatments may follow.
The Human Story: The Moment of Discovery
The silence in the room when the first results appeared lasted only a few seconds. Then someone spoke. “Check the numbers again.” They checked. The numbers were correct.
The team discussed what the result might mean. They debated whether to believe it. They decided to treat it as a hypothesis rather than a conclusion. They would test it in every way they could.
That moment of silence contained the entire arc of the next decade. Doubt, curiosity, determination, and eventually understanding. All compressed into a few seconds before anyone spoke.
The Scientific Story: The Publication
The paper in Genome Medicine is titled “Genetic variants in PAM confer GLP-1 resistance and impair response to GLP-1 receptor agonists in Type 2 diabetes.” It describes the human experiments, the mouse studies, and the clinical trial analyses.
The journal is peer-reviewed, meaning other scientists evaluated the work before publication. The reviewers asked questions and requested additional analyses. The authors responded and revised the manuscript.
The final version represents a consensus among the authors and reviewers that the findings are robust and meaningful.
The Human Story: The Patients Who Waited
Patients with diabetes have been waiting for precision medicine for decades. They have heard promises that genetics would transform their care. They have seen little change in how their doctors prescribe medications.
The PAM discovery is a step toward fulfilling that promise. It is not the final step. But it is a real step, based on real data, with real clinical implications.
The patients who participated in the studies, who gave their blood and their time, contributed to this step. They may not benefit directly. But future patients will.
The Scientific Story: The Unresolved Mechanism
The team has identified the variants. They have confirmed the resistance. They have shown the clinical impact. But the mechanism remains unknown.
“We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about,” Gloyn said. “No matter what we’ve done, we’ve not been able to nail precisely why they are resistant.”
This is the frontier. The next set of experiments will focus on the downstream signaling pathway. They will look at second messengers like cAMP and calcium. They will examine gene expression changes. They will search for the missing link between receptor activation and cellular response.
The Human Story: The Open Question
The study ends with an open question — not a solved problem or a neat conclusion, but a question that points toward the next discovery. The researchers do not know the answers yet, but they know where to look.
What is happening inside the cells of people with PAM variants? Why does their GLP-1 not work as well? And can we fix it?
The researchers do not know the answers yet. But they know where to look. That is the value of the study. It does not close a door. It opens one.
The Scientific Story: The Path Forward
The path forward involves several parallel tracks. One track focuses on the mechanism. Another track focuses on clinical implementation. A third track focuses on broader genetic screening.
Each track requires different expertise and resources. The mechanism track needs molecular biologists and biochemists. The clinical track needs physicians and genetic counselors. The screening track needs epidemiologists and health economists.
The PAM discovery has created a framework for all three tracks. The mechanism is unknown but bounded. The clinical impact is real but unmeasured in prospective studies. The screening potential is clear but unvalidated in practice.
The Human Story: The Legacy
Ten years of work. Four countries. Three clinical trials. Two genetic variants. One discovery.
The discovery will outlast the researchers who made it. It will be cited in textbooks. It will be taught to medical students. It will influence prescribing decisions for years to come.
Gloyn, Stoffel, Umapathysivam, and Araldi have contributed something durable to the understanding of diabetes. They have identified a reason why some patients do not respond to a blockbuster drug. They have opened a door to better treatment.
That is the legacy of their decade of work.
The Scientific Story: The Bigger Picture
Diabetes is a disease of 500 million people worldwide. GLP-1 drugs are among the most effective treatments available. But they do not work for everyone.
The PAM discovery explains some of that variation. It identifies a specific genetic mechanism that impairs drug response. It offers a path to better matching of patients to treatments.
Precision medicine is often discussed as a future goal. The PAM discovery brings it closer to the present. It is not the whole solution. But it is a real step.
The Human Story: The Silence That Started It All
The room went quiet. The screen showed numbers that contradicted every expectation. Nobody spoke for a moment.
That silence contained the beginning of a decade-long investigation. It contained the doubt that drove replication. It contained the curiosity that sustained the work. It contained the determination that led to publication.
And it contained the question that remains unanswered: Why?
The researchers are still working on that question. They do not know the answer yet. But they know where to look. And they know that the answer, when it comes, will change how diabetes is treated.
The silence was not empty. It was full of possibility.
Sources
3. ETH Zurich
4. Institute of Molecular Health Sciences
7. MIT